Common Contracts
19 similar Joint Filing Agreement contracts by Biotechnology Value Fund L P
Joint Filing AgreementJoint Filing Agreement • February 17th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Amendment No. 2 to Schedule 13G dated February 17, 2015 with respect to the shares of Common Stock of Aeolus Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • February 17th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Amendment No. 5 to Schedule 13G dated February 17, 2015 with respect to the shares of Common Stock of Array BioPharma Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • February 17th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Amendment No. 4 to Schedule 13G dated February 13, 2015 with respect to the shares of Common Stock of ChemoCentryx, Inc.., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • February 17th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Amendment No. 1 to Schedule 13G dated February 13, 2015 with respect to the shares of Common Stock of Cytokinetics, Incorporated., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • February 17th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Amendment No. 7 to Schedule 13G dated February 13, 2015 with respect to the shares of Common Stock of Capstone Therapeutics Corp., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • August 22nd, 2014 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated August 22, 2014 with respect to the shares of Common Stock of Receptos, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • August 21st, 2014 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Amended Statement on Schedule 13G dated August 21, 2014 with respect to the shares of Common Stock of Ligand Pharmaceuticals Incorporated, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • March 1st, 2013 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated March 1, 2013 with respect to the shares of Common Stock of Aeolus Pharmaceuticals, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • February 15th, 2013 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated February 15, 2013 with respect to the shares of Common Stock of Oncothyreon Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • July 16th, 2012 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated July 16, 2012 with respect to the shares of Common Stock of QLT Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • May 29th, 2012 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated May 29, 2012 with respect to the shares of Common Stock of ChemoCentryx, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
JOINT FILING AGREEMENTJoint Filing Agreement • December 23rd, 2011 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated December 23, 2011 with respect to the shares of Common Stock of Nektar Therapeutics, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • October 28th, 2011 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated October 28, 2011 with respect to the shares of Common Stock of Myrexis, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • October 21st, 2011 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated October 21, 2011 with respect to the shares of Common Stock of Affymax, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • October 13th, 2011 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated October 13, 2011 with respect to the shares of Common Stock of GenVec, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • July 29th, 2011 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated July 29, 2011 with respect to the shares of Common Stock of Icagen, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • July 8th, 2011 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated July 8, 2011 with respect to the shares of Common Stock of A.P. Pharma, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • June 6th, 2011 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated June 6, 2011 with respect to the shares of Common Stock of Rigel Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • March 3rd, 2011 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated March 3, 2011 with respect to the shares of Common Stock of Palatin Technologies, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
